Microbot Medical Inc. (NASDAQ:MBOT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have earned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $7.50.

Separately, B. Riley Financial assumed coverage on Microbot Medical in a research note on Tuesday, February 10th. They set a “buy” rating for the company.

Microbot Medical Price Performance

Shares of MBOT opened at $2.29 on Wednesday. The company has a market cap of $153.80 million, a P/E ratio of -7.90 and a beta of 1.19. The stock has a fifty day moving average price of $2.30 and a 200 day moving average price of $2.35. Microbot Medical has a 12 month low of $1.35 and a 12 month high of $4.67.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Thursday, March 26th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. As a group, research analysts anticipate that Microbot Medical will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Microbot Medical by 14.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock worth $7,148,000 after buying an additional 292,923 shares during the last quarter. CIBC Private Wealth Group LLC grew its stake in Microbot Medical by 1.8% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,480,000 shares of the biotechnology company’s stock worth $2,960,000 after buying an additional 26,000 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in Microbot Medical during the 3rd quarter worth $4,435,000. Heights Capital Management Inc. bought a new position in Microbot Medical during the 3rd quarter worth $2,693,000. Finally, Geode Capital Management LLC grew its stake in Microbot Medical by 54.4% during the 4th quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock worth $1,524,000 after buying an additional 268,609 shares during the last quarter. 16.30% of the stock is currently owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.